A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer

被引：0
|
作者：
Wu, Jiong
Zhang, Jian
Tong, Zhongsheng
Wang, Yongsheng
Zhang, Qingyuan
Cheng, Qiao
Chen, Xin
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[3] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[4] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[5] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[6] Second Peoples Hosp Yibin, Yibin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13091
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
    Wang, Hanwen
    Ma, Huilin
    Sove, Richard J.
    Emens, Leisha A.
    Popel, Aleksander S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [22] Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
    Liu, Yin
    Fan, Lei
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    ONCOLOGIST, 2023, 28 (01): : 86 - +
  • [23] Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with locally advanced triple negative breast cancer
    Yuan, Y.
    Frankel, P.
    Li, M.
    Kruper, L.
    Jones, V.
    Treece, T.
    Waisman, J.
    Yim, J.
    Tumyan, L.
    Schmolze, D.
    Hurria, A.
    Yeon, C.
    Mortimer, J.
    Somlo, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [24] An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple-negative breast cancer
    Tripathy, D.
    Ukrainskyj, S. M.
    Yang, Z.
    Kania, M.
    Schelman, W.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S514 - S514
  • [25] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [26] PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
    Kolbin, A.
    Velum, I
    Balykina, Y.
    Proskurin, M.
    VALUE IN HEALTH, 2019, 22 : S510 - S510
  • [27] A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.
    Zhao, Yannan
    Lv, Fangfang
    Chen, Shen
    Lu, Yunhua
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Zheng, Chunlei
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A singlearm, open-label, phase II study
    Wang, C.
    Liu, Z.
    Chen, X.
    Qiao, J.
    Li, L.
    Lu, Z.
    Sun, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S436 - S436
  • [29] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Jiang, Zefei
    Ouyang, Quchang
    Sun, Tao
    Zhang, Qingyuan
    Teng, Yuee
    Cui, Jiuwei
    Wang, Haibo
    Yin, Yongmei
    Wang, Xiaojia
    Zhou, Xin
    Wang, Yongsheng
    Sun, Gang
    Wang, Jingfen
    Zhang, Lili
    Yang, Jin
    Qian, Jun
    Yan, Min
    Liu, Xinlan
    Yi, Tienan
    Cheng, Ying
    Li, Man
    Zang, Aimin
    Wang, Shusen
    Wang, Chuan
    Wu, Xinhong
    Cheng, Jing
    Li, Hui
    Lin, Ying
    Geng, Cuizhi
    Gu, Kangsheng
    Xie, Chunwei
    Xiong, Huihua
    Wu, Xiaohong
    Yang, Junlan
    Li, Qingshan
    Chen, Yiding
    Li, Fanfan
    Zhang, Anqin
    Zhang, Yongqiang
    Wu, Yudong
    Nie, Jianyun
    Liu, Qiang
    Wang, Kun
    Mo, Xueli
    Chen, Lilin
    Pan, Yueyin
    Fu, Peifen
    Zhang, Helong
    Pang, Danmei
    Sheng, Yuan
    NATURE MEDICINE, 2024, 30 (02) : 249 - 256
  • [30] Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study
    He, Min
    Hao, Shuang
    Ma, LinXiaoxi
    Xiu, BingQiu
    Yang, BenLong
    Wang, ZeHao
    Xue, JingYan
    Chi, YaYun
    Xiong, Min
    Chen, Jiajian
    Huang, XiaoYan
    Liu, XiYu
    Wu, SongYang
    Xiao, Qin
    Huang, Yan
    Shui, RuoHong
    Cao, AYong
    Li, JunJie
    Di, GenHong
    Yang, WenTao
    Hu, Xin
    Liu, GuangYu
    Yu, KeDa
    Jiang, YiZhou
    Wang, ZhongHua
    Shao, ZhiMing
    Wu, Jiong
    ECLINICALMEDICINE, 2024, 74
12345